| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8536955 | Pharmacology & Therapeutics | 2018 | 84 Pages |
Abstract
Additional data is needed as the number of NPS continues to increase. Also, the effect fingerprints we have obtained are still incomplete and suffer from a large variation in the reported effects and effect sizes. Dedicated in vitro screening batteries will aid in complementing specific effect fingerprints of NPS. These fingerprints can be implemented in the risk assessments of NPS that are necessary for eventual control measures to reduce Public Health risks.
Keywords
JWH-018AMPAMDPV5-HTN-methyl-d-aspartateGPCRCOMTVGCCsMDMAEWStetrahydrocannabinolBPFUNODCNMDAα-PVP25B-NBOMe25I-NBOMe4-MEC1-Benzylpiperazine4-FA2C-B5-APBTFMPPEMCDDAMXE1-(3-chlorophenyl)piperazineTHCMAO-A3,4-Methylenedioxypyrovalerone25C-NBOMeEC50mCPPCatechol-O-methyltransferaseIC50PCP3,4-methylenedioxymethamphetamineBzPG-protein coupled receptorNPsAChEuropean UnionAcetylcholineα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acidγ-aminobutyric acidTransportersDesigner drugsUnited Nations Office on Drugs and CrimeDopamineSerotoninEarly warning systemNeuropharmacologyNeurotoxicologyNew psychoactive substanceEuropean Monitoring Centre for Drugs and Drug Addictionmonoamine oxidase AMechanism of actionnorepinephrineCannabinoidvoltage-gated calcium channelsGABAmuscarinic acetylcholine receptornicotinic acetylcholine receptorReceptors
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology
Authors
Laura Hondebrink, Anne Zwartsen, Remco H.S. Westerink,